Your search history is turned on.
Date: April 7, 2021 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Microsoft Word - 51-105F1 [F].doc Form 51-105F1 Notice OTC Issuer Ceases to be an OTC Reporting Issuer This is the form required under paragraph 4 (1) (d) of Multilateral Instrument 51-105 Issuers Quoted in the U.S. Over-the-Counter Markets for an OTC issuer to give notice that it has ceased to be an OTC reporting issuer under section 3 of the Instrument in a ...
Date: March 17, 2021 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
_ 1 Form 52-109F1 Certification of Annual Filings Full Certificate I, Adeel Ahmad, the Chief Financial Officer of ADVANZ PHARMA Corp. Limited, certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information t...
_ 1 Form 52-109F1 Certification of Annual Filings Full Certificate I, Graeme Duncan, the Chief Executive Officer of ADVANZ PHARMA Corp. Limited, certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information...
ADVZ MD&A Q4 2020 2020 ANNUAL MANAGEMENTS DISCUSSION AND ANALYSIS March17, 2021 Table of Contents 1 Management's Discussion and Analysis......................... 2 2 Business Overview, Corporate Strategy and Segments. 3 3 Recent Events.................................................................. 5 4 Results of Operations..................
Blank FORM 13-502F3A CLASS 3A REPORTING ISSUERS -- PARTICIPATION FEE MANAGEMENT CERTIFICATION I, Adeel Ahmad , an of ficer of the reporting issuer noted below have examined this Form 13-502F3A (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonab...
Consolidated Financial Statements of ADVANZ PHARMA Corp. Limited December 31, 2020 Table of Contents Independent Auditor's Report.................................................................................................................... 3 - 11 Consolidated Balance Sheets..........................................................................
FORM 13-501F4 CLASS 3A REPORTING ISSUERS - PARTICIPATION FEE MANAGEMENT CERTIFICATION I, Adeel Ahmad, an officer of the reporting issuer noted below have examined this Form 13- 501F4 (the Form) being submitted hereunder to the Alberta Securities Commission and certify that to my knowledge, having exercised...
ADVANZ PHARMA Corp. Limited Announces Fourth Quarter and 2020 Results 2020 revenue of $526 million and fourth quarter 2020 revenue of $135 million 2020 net loss of $75 million and fourth quarter net income of $2.4 million 2020 Adjusted EBITDA1 of $233 million and fourth quarter 2020 Adjusted EBITDA1 of $51 million Generated cash flow f...
Date: March 3, 2021 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
i EU-DOCS\31604538.2 CONTENTS Clause Page 1. DEFINITIONS AND INTERPRETATION .......................................................................... 2 2. COMPOSITION OF THE BOARD ..................................................................................... 13 3. COMMITTEES .........................................................................................................................
VIA ELECTRONIC TRANSMISSION TO ALL APPLICABLE EXCHANGES AND COMMISSIONS: RE: ADVANZ PHARMA CORP. LIMITED 1 Proxy (Court Meeting) on Blue Paper - Registered Securityholders, Auditor and Directors 2 Voting Instruction Form (Court Meeting) on Blue Paper - NOBOs 3 Proxy (General Meeting) on White Paper - Registered Securityholders, Auditor and Directors 4 Vo...